|
Re: BETonMACE Prespecified Cognition Assessment Results - Post-CTAD Conference Call - Transcript - 191206
|
4
|
Resverlogix Corp.
|
Dec 08, 2019 02:31PM
|
|
Re: Breakthrough Therapy Designation Application
|
4
|
Resverlogix Corp.
|
Dec 06, 2019 11:33AM
|
|
Re: Clinicaltrials.gov
|
4
|
Zenith Epigenetics
|
May 13, 2018 05:19PM
|
|
Re: WHY
|
4
|
Resverlogix Corp.
|
Oct 10, 2019 12:20PM
|
|
Re: The 34.4 million
|
4
|
Zenith Epigenetics
|
Dec 08, 2015 04:16PM
|
|
Re: NYAS Symposium on Apr 28
|
4
|
Resverlogix Corp.
|
Apr 21, 2016 10:17PM
|
|
New publication: RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
|
4
|
Resverlogix Corp.
|
Jun 13, 2016 04:30PM
|
|
Re: New patent (January)
|
4
|
Resverlogix Corp.
|
Feb 25, 2016 05:19AM
|
|
Re: BETonMACE Enrollment
|
4
|
Resverlogix Corp.
|
Feb 08, 2019 10:07AM
|
|
Re: BET inhibitors promising therapy for rare pediatric brain tumor
|
4
|
Zenith Epigenetics
|
Mar 01, 2017 12:48PM
|
|
Re: Events
|
4
|
Zenith Epigenetics
|
Apr 25, 2017 05:28PM
|
|
Re: Question about Phase 2
|
4
|
Resverlogix Corp.
|
Mar 12, 2019 10:48AM
|
|
Re: AGM agendas - Meetings Oct 31
|
4
|
Resverlogix Corp.
|
Oct 10, 2019 12:36PM
|
|
Re: Biotech Showcase, Jan 13-15
|
4
|
Resverlogix Corp.
|
Jan 07, 2020 10:18AM
|
|
Re: Clarification on BETonMACE baseline data
|
4
|
Resverlogix Corp.
|
Sep 04, 2019 02:56PM
|
|
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
4
|
Zenith Epigenetics
|
Mar 15, 2021 01:12PM
|
|
Re: futility ... comments/thoughts...
|
4
|
Resverlogix Corp.
|
Nov 08, 2016 02:30PM
|
|
Apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation
|
4
|
Resverlogix Corp.
|
May 25, 2018 10:10AM
|
|
Re: What if
|
4
|
Resverlogix Corp.
|
Mar 08, 2019 02:28PM
|
|
Re: The Pfizer connection...
|
4
|
Resverlogix Corp.
|
Dec 01, 2018 09:16AM
|
